|
ISPOR 8th Annual European Congress
6-8
November 2005, Palazzo Degli Affari, Florence, Italy
“INCORPORATING VALUES INTO HEALTH CARE DECISIONS” |
|
MONDAY, 7 NOVEMBER 2005 |
|
7:30 - 8:45 |
Round Table Breakfast Discussions |
| |
Harmonizing Health Economics
Discussion Leaders: Lieven Annemans PhD, MSc, Mman,
Professor & Senior Consultant, Ghent University, HEDM and IMS Health,
Meise, Belgium; Nancy Kline Leidy PhD, President and CEO, The
MEDTAP Institute at UBC, Bethesda, MD, USA
Is the US really in step with Europe? Does cost-utility analysis have
the same role in the US and Europe? Does cost/QALY have the same
relevance for US decision makers as for their European counterparts?
Valuing Health: Whose Values Count, Whose Values Should Count?
Discussion Leaders: Jeremy Chancellor BSc, MSc, Managing Director,
European Operations, Innovus Research (UK) Ltd, Bucks, UK; Judith
Barr, MEd, ScD, Associate Professor and Director, National Education
and Research Center for Outcomes Assessment, Northeastern University,
Boston, MA, USA
Measuring the value of health benefits is central to the evaluation of
treatment. If economic evaluation is based on societal values is there
a role for patients' values in measuring outcomes?
Bridging the Gap: Linking Clinical and Economic Outcomes Data
Discussion Leaders: Michael Nichol PhD, Associate Professor & Chair,
University of Southern California, Dept of Pharm Econ & Policy, Los
Angeles, CA, USA; Paul Kind, Principal Investigator, Centre for
Health Economics, Outcomes Research Group, University of York, York,
UK
Clinical studies often incorporate measures that are useful in
evaluating questions around safety/efficacy. But can health economists
adapt those outcome data for economic evaluation and if so, how?
|
| 8:00
- 9:00 |
Contributed Poster Presentations - Session I Viewing |
| 9:00
- 10:30 |
Second Plenary Session |
| |
Health Care Decision Makers Facing the Budget Allocation Dilemma:
Compressing Mortality vs Compressing Morbidity
Moderator: Lieven Annemans PhD, MSc, Mman,
Professor & Senior Consultant, Ghent University, HEDM and IMS Health,
Meise, Belgium
Speakers: Dr. Claudio Cricelli, President, Società Italiana di Medicina
Generale, Firenze, Italy;
Dr. Giovanna Scroccaro, President, Societa'
Italiana di Farmacia Ospedaliera, Milan, Italy; Patrizia Berto, PharmD,
MBA, President, PBE Consulting, Verona, Italy
This plenary session will discuss the issue of an aging population and
the challenge for decision-makers to fund traditional therapies aimed
at reducing mortality from chronic (eg cardiovascular, diabetes)
diseases
while still saving room for reducing morbidity with emerging expensive
treatments. How do they address this challenge? |
| 10:30
- 10:45 |
Break |
| 10:45 - 11:45 |
Contributed Workshops Session II -
See workshops details |
| |
CLINICAL STUDY METHODOLOGY ISSUES
W9: META-ANALYSIS OF LONGITUDINAL DATA FOR ECONOMIC MODELS: AN
APPLICATION OF MULTI-OUTCOME MODELS
Discussion Leaders: Khajak J Ishak MSc, Senior Statistician, Caro
Research Institute, Montreal, QC, Canada; Robert W. Platt PhD,
Associate Professor, Department of Pediatrics & Epidemiology and
Biostatistics McGill University, Montreal, QC, Canada; J. Jaime Caro
MD, President & Scientific Director, Caro Research Institute,
Concord, MA, USA
ADHERENCE/COMPLIANCE ISSUES
W10: INCORPORATING MEASURES OF COMPLIANCE AND PERSISTENCE IN
PHARMACOECONOMIC EVALUATIONS
Discussion Leaders: Dyfrig Hughes PhD , Senior Research Fellow in
Pharmacoeconomics, Centre for the Economics of Health, University of
Wales, Bangor, UK; Warren Cowell MSc, Health Economist, Roche
Products Ltd, Welwyn Garden City, Hertfordshire, UK; Tamas Andras
Koncz MD, OR Manager, Outcomes Research and Evidence Based Medicine,
Pfizer Ltd, Tadworth, UK
COST STUDY METHODOLOGY ISSUES
W11: THE ADDED VALUE OF BAYESIAN BELIEF NETWORKS FOR DECISION MAKING
Discussion Leaders: G Baio PhD, Post Doc, Department of Statistical
Science, University College London, London, UK; JP Jansen PhD,
Project Manager, MAPI VALUES, Houten, Netherlands
HEALTH CARE COVERAGE AND REIMBURSEMENT ISSUES
W12: MIXED TREATMENT COMPARISONS
Discussion Leaders: Neil Stephen Hawkins MSc, Research Fellow,
Centre for Health Economics, University of York, Heslington, York,
UK; Mark J Sculpher MSc, PhD, Professor, Centre for Health
Economics, University of York; Heslington, York, UK; Steve Palmer
MSc, Centre for Health Economics, University of York, Heslington,
York, UK
HEALTH CARE POLICY DEVELOPMENT ISSUES
W13: PRICING POTENTIAL OF A NEW DRUG: APPLICATION OF THE PRICING
MATRIX MODEL
Discussion Leaders: Mark JC Nuijten PhD, MD, MBA, Consultant,
Erasmus University, Rotterdam, Netherlands
W14: KEY ISSUES IN MARKET ACCESS: FRANCE, SPAIN, AND ITALY
Discussion Leaders: Xavier Badia MD, PhD,
Managing Director, Health Outcomes Research Europe, Barcelona, Spain;
Annie Chicoye PhD, Aremis Consultants, Neuilly sur Seine,
France; Regina Múzquiz PhD, Director of Public Affairs,
Sanofi-Aventis, Madrid, Spain; Cristina Negrini BSc, Director,
Pbe Consulting, Milan, Italy
PREFERENCE-BASED STUDIES
W15: CONJOINT ANALYSIS: APPLICATION TO GLOBAL PRICING AND
REIMBURSEMENT STRATEGY
Discussion Leaders: F. Reed Johnson PhD, Senior Fellow and Principal
Economist, RTI Health Solutions, Research Triangle Park, NC, USA;
Deirdre M Mladsi BA, Global Head, RTI Health Solutions, Research
Triangle Park, NC, USA; Keiron Sparrowhawk MSc, MBA, Principal,
PriceSpective Ltd, Buntingford, UK
QOL/PRO METHODOLOGY ISSUES
W16: THE USE OF COMPOSITE ENDPOINTS: A REVIEW OF THE REGULATORS
PERSPECTIVE AND METHODOLOGICAL ISSUES
Discussion Leaders: Christine De la Loge MSc, Project Manager, Mapi
Values, Lyon, France; Benoit Arnould MSc, MA, Project Manager, Mapi
Values, Lyon, France
|
| 11:45
- 13:15 |
Lunch, Exhibits & Contributed Poster Presentations - Session
II |
 |
ISPOR 10 YEAR CELEBRATION |
| 12.00 – 13.00 |
IMS Satellite Symposium -
Room 1A |
| |
" TRANSFERRING HEALTH ECONOMIC METHODS AND
RESULTS FROM ONE COUNTRY TO ANOTHER: ISSUES AND POSSIBLE SOLUTIONS”-
An IMS Health Symposium
Issues in transferring health economic methods and results from one
country to another as well as potential solutions will be presented
and discussed. Specific topics like differences in medical practice,
differences in cost structures, difference in data availability will
be covered.
OPENING REMARKS
Moderator: Lieven Annemans, PhD, MSc, MMan,
Principal Health Economics and Outcomes Research, Brussels, Belgium
ISSUES IN TRANSFERRING METHODS AND RESULTS OF HEALTH ECONOMIC
EVALUATIONS FROM ONE COUNTRY TO ANOTHER
Speaker: Jens Grüger, PhD, Global Head, Pricing &
Health Economics, Novartis Pharma AG, Basel, Switzerland
Assessing the value for money of health technologies is mostly done on
an individual country level. This is explained by the observation that
health economic evaluation results can be quite different from country
to country depending on differences in medical practice, cost
structures, cost level etc… Besides the question regarding how far one
should go in this individual country adaptation (i.e. up to one
evaluation for each country?) this lecture discusses also the
different issues that researchers face when the results of a health
economic evaluation conducted in a country X need to be reproduced in
a country.
POTENTIAL SOLUTIONS FOR HANDLING MULTI-COUNTRY
HEALTH ECONOMIC EVALUATION ISSUES
Speaker: Frank-Ulrich Fricke, PhD, MSc, Principal Health
Economics and Outcomes Research, Fricke & Pirk GmbH – A unit of IMS,
Nürnberg
Based on experience with multi-country projects, this lecture provides
suggestions about how some of the above mentioned issues could be
resolved. It will be shown that solutions strongly depend on the
objectives of multi-country projects and that there is not a “one and
only” solution. In the light of the “cost-effectiveness of a
cost-effectiveness study” it will appear that some solutions are more
cost-effective than others. A final word is addressed regarding the
geographical differences in societal willingness to pay for a unit of
health benefit.
OPEN DISCUSSION
|
| 13:15
- 14:15 |
Contributed Podium Presentations - Session II (4 podium groups
with 4 presentations per group) |
| |
Health Care Use And Policy: Focus On Health
ProfessionalsHP1 IDENTIFYING PREDICTORS OF OFF-LABEL
UTILIZATION PATTERNS OF TWO BIOTECHNOLOGY DRUGS, RECOMBINANT
ERYTHROPOIETIN ALFA AND DARBEPOETIN ALFA: A MULTI-HOSPITAL STUDY
Patkar AD, Holdford DA, Peterson SP Virginia Commonwealth
University, Richmond, VA, USA
HP2 PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS
IN A LONG TERM CARE SETTING
Wegner S1, Trygstad T2, Christensen DB2 1 AccessCare, Inc,
Morrisville, NC, USA; 2 University of North Carolina, Chapel Hill, NC,
USA
HP3 PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED
STATES OUTPATIENT SETTINGS: FACTORS AFFECTING PRESCRIPTION OF HIGH
ABUSE POTENTIAL AND COSTLY MEDICATIONS
Rasu R1, Balkrishnan R2, Shenolikar R2, Nahata M2 1 University
of Missouri Kansas City, Kansas City, MO, USA; 2 Ohio State University
College of Pharmacy, Columbus, OH, USA
HP4 PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY – WHAT DO THE
PATIENTS WANT?
Kielhorn H1, Wolter AB1, Schoenermark MP2 1 Schoenermark,
Kielhorn and Collegen, Hannover, Germany; 2 Hannover Medical School,
Hannover, Germany
Methods And Concepts In Patient-Oriented Research
PO1 TRAJECTORIES OF EQ-5D QUALITY OF LIFE UTILITY SCORES FOR
10,000 SCHIZOPHRENIA OUTPATIENTS OVER 2 YEARS: A REPORT FROM THE SOHO
STUDY
Hammond GC1, Croudace TJ1, Jones PB1, Belger M2, Novick D2 1
University of Cambridge, Cambridge, United Kingdom; 2 Eli Lilly and
Company Ltd, Windlesham, Surrey, United Kingdom
PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE
SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A
Pare P1, Lam SY2, Balshaw R3, Morin I3, Khorasheh S3, Barbeau M4,
Kelly S4, Dastani H5, McBurney C6
1 Centre Hospitalier affilie Universitaire de Quebec, Quebec, QC,
Canada; 2 Hawse Clinic, Calgary, AB, Canada; 3 Syreon Corporation,
Vancouver, BC, Canada; 4 Novartis Pharmaceuticals Inc (Canada), Dorval,
QC, Canada; 5 Novartis Pharmaceuticals Corp, East Hanover, NJ, USA; 6
Novartis Pharma AG, Basel, Switzerland
PO3 CLASSIFYING AND PREDICTING ANTIPSYCHOTIC ADHERENCE AMONG
SCHIZOPHRENIA OUTPATIENTS IN EUROPE: A LATENT CLASS ANALYSIS
Croudace TJ1, Jones PB1, Hammond GC1, Brown J2, Shi L3 1
University of Cambridge, Cambridge, United Kingdom; 2 Eli Lilly and
Company Ltd, Windlesham, Surrey, United Kingdom; 3 Tulane University,
New Orleans, LA, USA
PO4 EVIDENCE-BASED MEDICINE IN CHINA
A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN
PATIENTS WITH ADVANCED COLORECTAL CANCER (ACC): "CCRA-QOL"
Perulero N1, Badia X1, Marfá X2, Guallar JL2
1Health Outcomes Research Europe, Barcelona, Spain, 2Sanofi - Aventis,
S.A.U, Barcelona, Spain
PCN41 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY
OF LIFE (HRQOL) IN PATIENTS WITH ADVANCED COLORECTAL CANCER (ACC):
“CCRA-QOL”
Perulero N1,
Badia X1, Marfá X2, Guallar JL2
1Health Outcomes Research Europe, Barcelona, Spain; 2
Sanofi – Aventis, S.A.U, Barcelona, Spain
Health Related Quality Of Life Based Patient Reported Outcomes:
Session 1
QL1 DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE
OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)
Coyne KS1, Matza L1, Kopp Z2, Jumadilova Z2, Thompson C1,
Khullar V3 1 The MEDTAP Institute at UBC, Bethesda, MD, USA; 2 Pfizer
Inc, New York, NY, USA; 3 Imperial College, School of Medicine,
London, United Kingdom
QL2 TESTING THE CROSS-WALK: SALVAGING CANCER SPECIFIC MEASURES FOR
USE IN ECONOMIC EVALUATION
Wilson TR1, Kind P2 1 University of York, York, United Kingdom;
2 Outcomes Research Group, York, United Kingdom
QL3 “FAMIDIAL STUDY”: ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS
PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON
DIALYSIS PATIENTS‘ HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN
Alvarez-ude F1, Rebollo P2, Valdes C2, Estebanez C1
1 Hospital General de Segovia. Instutute "Reina Sofía "for
Nephrological Research, Segovia, Segovia, Spain; 2 Hospital
Universitario Central de Asturias and Institute Reina Sofia for
nephrological research, Oviedo, Asturias, Spain
QL4 VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA
IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY
Johnson LL1, Miller KL1, Miller DP1, Colwell HH1, Bhattacharyya SK2,
Deeter RG2, Mathias SD1 1Ovation Research Group, San Francisco,
CA, USA; 2 Amgen, Inc, Thousand Oaks, CA, USA
Cost Evaluation Studies In Interventional Cardiology
IC1 THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS BASED ON THE A
SYNTHESIS OF THE RESULTS OF 15 RANDOMISED CONTROLLED TRIALS
Hawkins N, Sculpher M Unversity of York, York, United Kingdom
IC2 PREDICTING THE COST-EFFECTIVENESS OF THE ABT-578 COATED DRIVER
CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS
Remák E1, Hutton J1, Oliver E2, Brasseur P3 1 The MEDTAP Institute at
UBC, London, United Kingdom; 2 Medtronic Ltd, Watford, United Kingdom;
3 Medtronic AG, Tolochenaz, Switzerland
IC3 HEALTH ECONOMIC EVALUATION OF BIVALIRUDIN IN THE MANAGEMENT OF
PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN BELGIUM
Ethgen O1, Lamotte M2, Annemans L2 1 University of Liège, Liège,
Belgium; 2 HEDM - IMS Health, Brussels, Belgium
IC4 ECONOMIC ANALYSIS OF THE STRATEGY STUDY: TIROFIBAN AND DRUG
ELUTING STENTS VERSUS ABCIXIMAB AND BARE METAL STENTS
Mittmann N1, Valgimigli M2, Percoco G3, Campo G3, Squasi P3, Arcozzi
C3, Malagutti P3, Ferrari R3, Seung SJ4, Isogai P1 1 Sunnybrook &
Women's Health Science Centre, Toronto, ON, Canada; 2 University of
Ferrara, Institue of Cardiology, Arcispedale S' Anna, Italy, Ferrara,
Italy; 3 University of Ferrara, Institue of Cardiology, Arcispedale S'
Anna, Ferrara, Italy, Italy; 4 HOPE Research Centre, Sunnybrook &
Women's College Health Sciences Centre, Toronto, ON, Canada
|
| 14:15
- 14:30 |
Break |
| 14:30
- 15:30 |
Contributed Podium Presentations - Session III (5 podium groups
with 4 presentations per group) |
| |
Health Care Use And
Policy: Focus On PatientsHP5 TREATMENT PATTERNS
AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY
BISPHOSPHONATE THERAPY
Huybrechts KF1, Ishak KJ2, Proskorovsky I2, Caro JJ1, Levinton
C1 1 Caro Research, Concord, MA, USA; 2 Caro Research, Dorval, QC,
Canada
HP6 EFFECT OF CO-PAYMENT ON COMPLIANCE TO STATINS AFTER CORONARY
HEART DISEASE HOSPITALIZATION
Ye X, St.Peter WL, Gross CR University of Minnesota,
Minneapolis, MN, USA
HP7 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN PRIVATE PAYER
TRANSPLANT RECIPIENTS
Lalla A1, Gilmore A1, Legorreta A2 1 Health Benchmarks, Inc,
Woodland Hills, CA, USA; 2 UCLA School of Public Health, Woodland
Hills, CA, USA
HP8 PATIENT CHARACTERICS, GLYCEMIC CONTROL, AND THE USE OF
ANTIDIABETIC AGENTS AMONG INDIVIDUALS DIAGNOSED WITH TYPE-2 DIABETES:
EVIDENCE FROM THE UK
Secnik K1, Yurgin N1, Lage MJ2, McDonald-Everett C1 1 Eli Lilly
and Company, Indianapolis, IN, USA; 2 HealthMetrics Outcomes Research,
LLC, Groton, CT, USA
Health Related Quality Of Life Based Patient Reported Outcomes:
Session 2
QL5 CLINICAL RESPONSES TO TREATMENT AND CHANGES IN THE
DERMATOLOGY LIFE QUALITY INDEX (DLQI) IN MODERATE TO SEVERE PLAQUE
PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
Shikiar R1, Thompson C2, Melilli LE3 1 MEDTAP Institute at
United Biosource Corporation, Seattle, WA, USA; 2 MEDTAP Institute at
United Biosource Corporation, Bethesda, MD, USA; 3 Abbott
Laboratories, Abbott Park, IL, USA
QL6 ADALIMUMAB REDUCES FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING
SPONDYLITIS (AS) — 6-MONTH RESULTS OF A CANADIAN AS STUDY
Luo MP1, Revicki D2, Rentz A2, Wong RL3, Maksymowych WP4 1
Abbott Laboratories, Abbott Park, IL, USA; 2 MEDTAP Institute at
United Biosource Corporation, Bethesda, MD, USA; 3 Abbott
Laboratories, Parsippany, NJ, USA; 4 University of Alberta Hospital,
Edmonton, AB, Canada
QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN
Prezioso D1, Zattoni F2, Pesce F3, Scarpa R4, Tubaro A5, Artibani W6,
Santini A7, The FLOW Study Group I8 1 Federico II University,
Naples, Italy; 2 S. Maria della Misericordia Hospital, Udine, Italy; 3
Policlinico GB Rossi, Verona, Italy; 4 San Luigi Gonzaga Hospital,
Turin, Italy; 5 S. Andrea Hospital, Rome, Italy; 6 University of
Padua, Padua, Italy; 7 Boehringer Ingelheim, Milan, Milan, Italy; 8
Italian Urology Centers, Virgilio, Italy
QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE
COCHE STUDY
Scalone L1, Gringeri A2, Von Mackensen S3, Mannucci PM2, De
Silvio S1, Anastasia M1, Di Stasi F1, Mantovani LG1 1 Center of
Pharmacoeconomics, University of Milan, Milan, Italy; 2 Haemophilia
and Thrombosis Centre, Milan, Italy; 3 Institute for Medical
Psychology, Hamburg, Germany
Cost Evaluation Studies In Diabetes And Neurological Disorders
DN1 ECONOMIC EVALUATIONOF SPECT-DATSCAN IN THE DIAGNOSIS OF
PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY
Busca R1, Antonini A2, Lopatriello S3, Berto P3 1 Pbe
Consulting, Milano, Italy; 2 Istituti Clinici di Perfezionamento,
Milano, Italy; 3 Pbe consulting, Verona, Italy
DN2 COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF
BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES.
Palmer AJ1, Dinneen S2, Gavin III JR3, Gray A4, Herman WH5,
Karter AJ6 1 CORE - Center for Outcomes Research, Binningen,
Switzerland; 2 National University of Ireland, Galway, Galway,
Ireland; 3 Emory University School of Medicine and Morehouse School of
Medicine, Fairburn, GA, USA; 4 University of Oxford, Oxford, United
Kingdom; 5 University of Michigan, Ann Arbor, MI, USA; 6 Kaiser
Permanente, Oakland, CA, USA
DN3 COST-EFFECTIVENESS OF NON-INVASIVE IMAGING IN THE DIAGNOSIS OF
PARKINSONISM
Brüggenjürgen B1, Smala A2, Chambers M3 1 Charité -
Universitätsmedizin Berlin, Institut für Sozialmedizin, Epidemiologie
und Gesundheitsökonomie, Berlin, Germany; 2 MERG - Medical Economics
Research Group, München, Germany; 3 Health Economics, GE Healthcare,
Little Chalfont, United Kingdom
DN4 PHARMACOECONONOMIC EVALUATION OF SEDATION WITH REMIFENTANIL/PROPOFOL
VERSUS MIDAZOLAM/FENTANYL IN THE INTENSIVE CARE UNIT
Muellejans B1, Matthey T1, Schill M2, Welte R2,1 Heart Centre
Mecklenburg-Vorpommern, Karlsburg, Germany; 2 GlaxoSmithKline, Munich,
Germany
Clinical Outcomes Studies CO1
VALIDATION OF DIAGNOSTIC PROCEDURES IN SYMPTOMATIC BENIGN PROSTATIC
HYPERPLASIA. CONCORDANCE BETWEEN INITIAL AND FINAL DIAGNOSIS IN DAILY
CLINICAL PRACTICE
Carballido J1, Badia X2, Gimeno A3, Regadera L4, Dal-Re R5, Guilera
M6 1 Hospital Puerta de Hierro, Madrid, Spain; 2 Health Outcomes
Research Europe Group, Barcelona, Cataluña, Spain; 3 Hospital General
La Mancha, Ciudad Real, Spain; 4 Glaxo Smith Kline, Madrid, Spain; 5
GlaxoSmithKline, Madrid, Spain; 6 Health Outcomes Research Europe,
Barcelona, Spain
CO2 EARLY GLYCEMIC CONTROL IMPROVES HEALTH AND ECONOMIC BENEFITS IN
TYPE 2 DIABETES: A MODEL BASED ANALYSIS
Eddy D1, Schlessinger L1, Patwardhan RN2 1 Kaiser
Permanente, Oakland, CA, USA; 2 GlaxoSmithKline, King of Prussia, PA,
USA
CO3 META-REGRESSION ASSESSMENT OF ATOMOXETINE EFFICACY USING
RANDOMIZED CONTROLLED ADHD TRIALS
Bae JP Eli Lilly and Company, Indianapolis, IN, USA
CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL
HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT
IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE
METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)
Oh WK1, Proctor K1, Nakabayashi M1, Evan C1, Tormey LK1,
Breierova L2, Smith M2, Neary M3, Duh MS2 1 Dana-Farber Cancer
Institute, Boston, MA, USA; 2 Analysis Group Inc, Boston, MA, USA; 3
F. Hoffmann-La Roche, Ltd, Basel, Switzerland
|
| 15:30
- 15:45 |
Break |
| 15:45 -
16:45 |
Issue Panels Session I - See Issue Panels Details |
| |
HEALTH POLICY/HEALTH CARE
REIMBURSEMENT/COVERAGE ISSUES
IP1: PAYOR ORIENTED EVIDENCE GUIDELINES
Moderator: Joseph Singer MD, VP, Integrated Research Network,
HealthCore, Inc, Wilmington, DE, USA
Panelists: James MacKay MD, Medical Director, Providence Health
Plan, Beaverton, OR, USA
QOL/PRO METHODOLOGY ISSUES
IP2: MEMORY AND PERCEPTION: THE ISSUE OF RECALL BIAS IN
PATIENT-REPORTED OUTCOMES
Moderator: Nancy Kline Leidy PhD,
President and CEO, The MEDTAP Institute at UBC, Bethesda, MD, USA
Panelists: Donald E. Stull PhD, Research
Scientist, The MEDTAP Institute at UBC, Bethesda, MD, USA; Olivier
Chassany, Département de la Recherche Clinique et du Développement
Assistance Publique, Hopitaux de Paris Hôpital Saint-Louis, Paris,
France
IP3: SUBMISSION OF PATIENT-REPORTED OUTCOMES TO THE EMEA AND THE
FDA: AREAS OF CONVERGENCE OR DIVERGENCE
Moderator: Patrick Marquis MBA, MD, Managing Director, Mapi Values,
Boston, MA, USA
Panelists: Laurie Burke RPh, MPH, Director, Study Endpoints and
Label Development, Food and Drug Administration, Rockville, MD, US;
Giovanni Apolone MD, Head of Translational and Outcomes Research
Lab, Mario Negri Institute, Milan, Italy
HEALTH TECHNOLOGY ASSESSMENT ISSUES
IP4: PROGRESS AND UNCERTAINTY IN HEALTH TECHNOLOGY ASSESSMENT
Moderator: Frank Papatheofanis MD, MPH, PhD, Associate Professor,
University of California San Diego, San Diego, CA, USA
Panelists: Uwe Siebert MD, MPH, MSc, Director, Cardiovascular
Research Program, Harvard Medical School, Boston, MA, USA
ISSUES ON USE OF HEALTH OUTCOMES RESEARCH INFORMATION BY
DECISION-MAKERS
IP5: EVALUATION OF DRUG SAFETY: CAN THE USE OF HEALTH ECONOMICS AND
OUTCOMES RESEARCH (HEOR) METHODS PRODUCE BETTER DECISIONS?
Moderator: John Hutton, BSc, BPhil, Senior Research Leader, United
BioSource Corporation, London, UK
Panelists: Francis Pang BSc, MSc, PhD, Head of Health Economics,
Abbott Laboratories Ltd, Maidenhead, Berkshire, UK; Clive Pritchard
PhD, Health Economist, Office of Health Economics, London, UK
|
| 16:45 - 17:00 |
Break |
| 17:00- 18:00
|
ISPOR
Forums |
| |
| 17:00-18:00 |
ISPOR EUROPEAN MEDICAL DEVICE AND
DIAGNOSTICS COUNCIL FORUM - WHEN AND HOW TO ASSESS MEDICAL DEVICE
AND DIAGNOSTICS: THE LEARNING CURVE ISSUE |
| |
Moderator: Rod Taylor
MSc, PhD, Senior Reader in Public Health & Epidemiology &
Director of MSC HTA Programme, Department of Public Health &
Epidemiology, University of Birmingham, Edgbaston, UK, Birmingham,
United Kingdom |
| |
Speakers: Patrick Galloo MD, CMO,
Social Sickness Funds, Brussels, Belgium and Fred
Lindemans, Vice-President and General Manager, Bakken Research
Centre, Maastricht, The Netherlands
|
|
17.00-18.00 |
MEDICATION COMPLIANCE & PERSISTENCE SPECIAL INTEREST GROUP
FORUM |
| |
Everyone is welcome to participate in this Forum.
Presentations will focus on the ongoing activities of Work Groups,
and reports in preparation. The audience will have opportunity for
discussions throughout the Forum. Please attend to learn more
about current activites and to how to join this SIG in any
capacity. Check the website in advance to familiarize yoiurself
with the scope of projects
http://www.ispor.org/sigs/medication.asp . |
|
17.00-17.05 |
Overview of the Medication Compliance Special Interest Group |
| |
Moderator: Joyce Cramer, BS Medication Compliance &
Persistence SIG Chair, & Associate Research Scientist, Yale
University School of Medicine, Department of Psychiatry, West
Haven, CT, USA |
|
17.05-17.10 |
Standardizing Medication Compliance and Treatment Persistence
Definitions |
| |
Speaker: Anita Burrell MS Definitions Working Group Co-Chair, & Global
Health Outcomes & Market Access Senior Director, Sanofi-Aventis,
Bridgewater, NJ, USA |
|
17.10-17.15 |
Standards for Analyses Of Medication Compliance And Treatment
Persistence |
| |
Speaker: Michael B. Nichol PhD, Analyses Standards Working Group
Chair & Department of Pharmaceutical Economics & Policy Chair,
University of Southern California, Los Angeles, CA, USA |
|
17.15-17.20 |
Educating Providers and Users Of Health Outcomes Data On Medication
Compliance |
| |
Speaker: Joyce Cramer, SIG Chair
[for Andrea Adamus, PhD, Hieu Tran PhD, Jasmanda Wu, PhD, MPH |
|
17.20-17.25 |
Standardizing Methods for Cost Analyses Related To Medication
Compliance and Treatment Persistence |
| |
Speaker: Dyfrig Hughes PhD, Economics of Compliance Working Group
Chair & Senior Research Fellow, University of Wales, Bangor, UK |
|
17.25-17.55 |
Breakout Group Discussions |
|
17.55-18.00 |
Close |
|
|
17:00-18:00 |
ISPOR USING ‘REAL
WORLD’ DATA IN COVERAGE AND REIMBURSEMENT DECISIONS TASK FORCE
FORUM |
|
|
Moderators:
Task Force Co-Chairs: Peter Neumann ScD, Associate
Professor of Policy and Decision Sciences, Harvard School of
Public Health , Boston, MA, USA, and Lou Garrison PhD,
Professor, Department of Pharmacy, University of Washington,
Seattle WA, US
Speakers: Deborah Marshall, PhD, Director, Research
& Development Health Economics & Outcomes Research, Innovus
Research Inc., ON, CANADA; Dan Mullins PhD, Professor and
Chair, Pharmaceutical Health Services, Research University of
Maryland School of Pharmacy, Baltimore, MD, USA; Pennifer
Erickson PhD, Co-founder, O.L.G.A., State College, PA, USA
The mission of the ISPOR Using “Real World” Data in Coverage and
Reimbursement Decisions Task Force is to develop an analytic
framework and action plan to assist health care decision-makers in
dealing with “real world” data and information. The Task Force is
describing the types of real-world data, defining the issues &
hierarchy of methods using real world data, developing an
understanding of benefits and challenges of “real world” data, and
defining the use of real world data in clinical outcomes studies,
economics outcomes studies, and quality of life/patient-reported
outcomes studies. The progress of this ISPOR Task Force will be
discussed during this Forum. |
|
|
17:00-18:00 |
ISPOR RUSSIAN CHAPTER FORUM -THE
REIMBURSEMENT SYSTEM DEVELOPMENT AND RATIONAL USE OF DRUGS |
|
|
Moderator: Pavel Vorobiev MD,
Professor, Moscow Medical Academy named after Sechenov, Head of
the Research Department on Health Care Standardization Problems,
Moscow, Russia
Speakers: Representative of the Federal Service on Surveillance
under Health Care and Social Development; ISPOR Representative;
Russian Regional Health Care Leader
|
|
|
17:00-18:00 |
ISPOR BUDGET
IMPACT TASK FORCE FORUM |
|
|
Moderators: Task Force Co-Chairs: Josephine
Mauskopf PhD, VP, Health Economics, RTI Health Solutions, RTI
International, Research Triangle Park, NC, USA; Sean Sullivan
MS, PhD, RPh, Professor and Director, University of
Washington, Pharmaceutical Outcomes Research and Policy Program,
Seattle, WA, USA |
|
|
Speakers: Lieven
Annemans MSc, PhD, Health Economist Ghent University, Senior
Consultant Global Health Economics, HEDM and IMS Health, Brussels,
Belgium;
J. Jaime Caro MD, Scientific Director, Caro Research,
Concord, MA, USA;
C. Daniel Mullins PhD, Professor and Chair, Pharmaceutical
Health Services Research, University of Maryland School of
Pharmacy, Baltimore, MD, USA; Mark Nuijten MBA, MD, PhD,
Sr. Research Scientist, Dir. of Business Dev., MEDTAP
International, Inc., Jisp, The Netherlands; Ewa Orlewska PhD,
Lecturer, Pharmacoeconomics Centre Warsaw, Warsaw; Paul Trueman
MA, Sales & Marketing Director, York Health Economics
Consortium, University of York, York, UK; John Watkins MPH, RPh,
Pharmacy Manager, Formulary Development, Premera Blue Cross,
Bothell, WA, USA; Andrew Wilson BMedSc, MB SC, FRACP, MSc,
Deputy Director and Professor of Public Health, University of
Queensland, School of Public Health, Brisbane, Australia
|
|
|
17:00-18:00 |
ISPOR PATIENT
REGISTRY SPECIAL INTEREST GROUP FORUM - PATIENT REGISTRIES:
OPPORTUNITY AND RESPONSIBILITY |
|
|
Key issues presented during this Forum will include the
capture of "real world" clinical, economic, and humanistic data
for a more accurate characterization of health care
interventions (drugs and devices) in actual medical practice as
well as patient survey commercialization, safety surveillance,
analytical methods, technology, and global initiatives. The
results of the ISPOR Patient Registry SIG Survey, an ISPOR
member survey to gain a better understanding of the needs of
users of patient registry information, will also be presented.
Moderator: Jeffrey Trotter MM, ISPOR Patient
Registry SIG Chair & President, Ovation Research Group, Highland
Park, IL, USA.
Speaker: Leanne Larson MHA, Senior Vice
President, Patient Registries, Ovation Research Group, Highland
Park, IL, USA
|
|
|
17:00-18:00 |
ISPOR
HEALTH CARE STRATEGY COUNCIL FORUM – A WORD FROM HEALTH CARE
DECISION-MAKERS ON OUTCOMES RESEARCH |
|
|
The goal of the ISPOR Health Care Strategy Council (an ISPOR
advisory council consisting of health care decision-makers from
USA, Canada, UK, and Germany) is to define areas of concern and
key issues within these areas with regard to outcomes research and
its use by health care decision-makers. During this Forum, key
issues in 5 key areas (education, training, communication –
pricing & market force – outcomes methods & standards –
availability, access & sharing – credibility & bias) will be
discussed.
|
|
17:00-17:05 |
Overview of the Health Care
Strategy Council |
|
|
Moderator: Marcus Wilson PharmD, ISPOR Health Care Strategy
Council Chair & President, HealthCore Inc., Wilmington, DE, USA |
|
17:05-17:10 |
Education, Training, &
Communication Key Issues & Council Recommendations |
|
|
Speakers: Dennis W Raisch PhD, Department
of Veterans Affairs, Clinical Research Pharmacy Coordinating
Center, Albuquerque, NM, USA; Brian Sweet B.S. Pharm, MBA,
WellPoint Pharmacy Management, West Hills, CA, USA |
|
17:10-17:20 |
Pricing, Market Force, Health
Policy, & Applicability Key Issues & Council Recommendations |
|
|
Speakers: Laurie Beth Burke RPh, MPH, FDA,
CDER, DDMAC, Rockville, MD, USA; Andreas Laupacis MD, MSc,
FRCPC, Institute for Clinical Evaluative Sciences, Toronto,
Canada |
|
17:20-17:30 |
Methods & Standards
Key Issues & Council Recommendations |
|
|
Speakers: Eugene Eavy R.Ph.,
MBA, St. Joseph Mercy Health System, Ann Arbor, MI, USA;
James MacKay MD, Providence Health Plan, Beaverton, OR, USA |
|
17:30-17:40 |
Availability, Access,
& Sharing Key Issue & Council Recommendations |
|
|
Speaker: Joseph Singer MD,
Integrated Research Network, HealthCore, Inc., Wilmington,
Delaware, USA |
|
17:40-17:50 |
Credibility,
Integrity, & Bias Key Issues & Council Recommendations |
|
|
Speakers: Marcus Wilson PharmD, Health
Core, Inc, Wilmington, DE, USA; Michael Drummond PhD,
University of York, Centre for Health Economics, Heslington, York,
UK |
|
17:50-18:00 |
Open Discussion
|
|
|
17:00-18:00 |
ISPOR STUDENT FORUM |
|
|
OUTCOMES RESEARCH: PAST,
PRESENT, AND FUTURE
Moderator: Josh Epstein, ISPOR Student
Network Chair and PhD Student, University of Southern California,
Los Angeles, CA, USA
THE ORIGINS OF OUTCOMES RESEARCH AND ITS PUBLIC HEALTH
IMPLICATIONS
Speaker: Abraham Hartzema PharmD, PhD, Professor and
Eminent Scholar, Pharmacy Health Care Administration, University
of Florida, Gainesville, FL USA
A GUIDE TO TYPES OF CLINICAL OUTCOME MEASURES
Speaker: Judith Barr, Associate Professor and
Director, Northeastern University, Boston, MA, USA
EXTENDING CROSS-SECTIONAL TIME PERIODS FOR UTILIZATION ANALYSES
Speaker: Michael Nichol PhD, Associate Professor &
Chair, University of Southern California, Los Angeles, CA USA
|
|
| 18:00 - 20:00 |
Exhibitors' Wine & Cheese Reception & Poster Presentations - Session
II |
|
|
ISPOR
10th ANNIVERSARY PARTY |
|
8th Annual European Congress Main Page |
|
